Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 431

1.
4.

Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections.

Walker AP, Nichols RL, Wilson RF, Bivens BA, Trunkey DD, Edmiston CE Jr, Smith JW, Condon RE.

Ann Surg. 1993 Feb;217(2):115-21.

7.

Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery.

Paladino JA, Rainstein MA, Serrianne DJ, Przylucki JE, Welage LS, Collura ML, Schentag JJ.

Pharmacotherapy. 1994 Nov-Dec;14(6):734-9.

PMID:
7885978
8.

Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis.

McGregor JA, Crombleholme WR, Newton E, Sweet RL, Tuomala R, Gibbs RS.

Obstet Gynecol. 1994 Jun;83(6):998-1004.

PMID:
8190448
9.
10.
11.

Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections.

Messick CR, Mamdani M, McNicholl IR, Danziger LH, Rodvold KA, Condon RE, Walker AP, Edmiston CE Jr.

Pharmacotherapy. 1998 Jan-Feb;18(1):175-83. Erratum in: Pharmacotherapy 1998 May-Jun;18(3):662.

PMID:
9469691
12.

Single-agent therapy for acute pelvic inflammatory disease: sulbactam/ampicillin versus cefoxitin.

Hemsell DL, Bawdon RE, Hemsell PG, Nobles BJ, Heard MC.

J Int Med Res. 1990;18 Suppl 4:85D-89D.

PMID:
2282973
13.

Sulbactam/ampicillin versus cefoxitin in the treatment of obstetric and gynaecological infections.

Senft HH, Stiglmayer R, Eibach HW, Koerner H.

Drugs. 1986;31 Suppl 2:18-21.

PMID:
3013568
14.

A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections.

Reinhardt JF, Johnston L, Ruane P, Johnson CC, Ingram-drake L, MacDonald K, Ward KW, Mathisen G, George WL, Finegold SM, et al.

Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S569-75.

PMID:
3026005
15.

Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess.

Allewelt M, Schüler P, Bölcskei PL, Mauch H, Lode H; Study Group on Aspiration Pneumonia.

Clin Microbiol Infect. 2004 Feb;10(2):163-70.

17.

Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections.

Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR.

Eur J Clin Microbiol Infect Dis. 1996 Dec;15(12):913-21.

PMID:
9031873
18.

Conversion of treatment from cefoxitin to ampicillin/sulbactam: experience in a university teaching hospital.

Kitrenos JG, Rotella DL, Nakasato S.

Adv Ther. 1995 Jan-Feb;12(1):30-43.

PMID:
10150321
19.

Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.

Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW.

Clin Infect Dis. 1994 May;18(5):683-93. Erratum in: Clin Infect Dis 1994 Oct;19(4):820.

PMID:
8075257
20.

[Acute bacterial salpingitis. The importance of residual inflammation. A comparative study with celioscopic control of 2 antibiotic protocols: sulbactam-ampicillin versus cefoxitin].

Le Bouedec G, Pouly JL, Mage G, Canis M, Wattiez A, Abbas Muhktar B, Bruhat MA.

J Gynecol Obstet Biol Reprod (Paris). 1990;19(6):765-72. French.

PMID:
2147930

Supplemental Content

Support Center